PTSD: National Center for PTSD
MDMA and Psilocybin Therapies for PTSD Treatment: Updates and Future Direction
Continuing Education
This section brings together free in-depth Continuing Education resources for the Professional community concerned with trauma.
MDMA and Psilocybin Therapies for PTSD Treatment: Updates and Future Direction
- Date Created: 11/15/2024
- Time to Complete: 1 hour
- Credits: ANCC, APA, ASWB, ACCME, NBCC, Other Orgs
- Skill Level: Intermediate
- Course Series: PTSD 101, PTSD Consultation Lecture Series
Author(s):
Description
Psychedelic-assisted therapy for the treatment of mental health conditions is receiving increased attention. Since the FDA designated MDMA and psilocybin breakthrough status, studies of MDMA- and psilocybin-assisted therapy for posttraumatic stress disorder (PTSD) and depression are growing.
This course provides an overview of the unique role psychedelics may play in the treatment of mental health conditions such as PTSD and depression. A review of the literature (pre-recording studies) is included, and important gaps in the field are identified. Clinical implications and future research for the use of psychedelics for PTSD and depression are highlighted.
Goals and Objectives
- Discuss why psychedelics such as MDMA and psilocybin may be helpful for assisting in the treatment of PTSD.
- Describe the current literature on MDMA and psilocybin for PTSD treatment.
- Identify at least 2 current gaps in this literature (at time of presentation).
- Discuss future research and clinical implications of psychedelics for PTSD treatment.
